Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: Results from two transplant centres

Stephen D. Smith, Craig Moskowitz, Robert Dean, Brad Pohlman, Ronald Sobecks, Edward Copelan, Steven Andresen, Brian Bolwell, Jocelyn C. Maragulia, Jill M. Vanak, John Sweetenham, Alison J. Moskowitz

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Prior series have demonstrated that early relapsed (within 1year) or refractory Hodgkin lymphoma (HL) is associated with poor prognosis. To determine the outcome for patients with early relapsed/refractory HL in the modern era, we combined data from two large transplant centres, Cleveland Clinic Taussig Cancer Institute (CCTCI) and Memorial Sloan-Kettering Cancer Center (MSKCC), and analysed consecutive patients transplanted for relapsed/refractory HL following induction failure or remission durations of <1year. Two hundred and fourteen patients were analysed and the event-free survival (EFS) and overall survival (OS) at 6years for all patients were 45% and 55%, respectively. Factors significant for prognosis in multivariate analysis were extranodal disease and bulky disease (≥5cm). Patients with 0, 1, or 2 risk factors achieved 6year EFS of 65%, 47%, and 24% and 6year OS of 81%, 55%, and 27%, respectively. Patients with the sole risk factor of early relapsed/refractory disease achieved good outcomes in this large series; however the presence of bulk and/or extranodal disease significantly reduced EFS and OS. Patients with these additional risk factors are best suited for clinical trials investigating novel salvage regimens and post-transplant maintenance strategies.

Original languageEnglish (US)
Pages (from-to)358-363
Number of pages6
JournalBritish Journal of Haematology
Volume153
Issue number3
DOIs
StatePublished - May 1 2011
Externally publishedYes

Fingerprint

Hodgkin Disease
Stem Cells
Transplants
Disease-Free Survival
Survival
Neoplasms
Multivariate Analysis
Maintenance
Clinical Trials

Keywords

  • Hodgkin lymphoma
  • Refractory
  • Relapse
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology

Cite this

Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma : Results from two transplant centres. / Smith, Stephen D.; Moskowitz, Craig; Dean, Robert; Pohlman, Brad; Sobecks, Ronald; Copelan, Edward; Andresen, Steven; Bolwell, Brian; Maragulia, Jocelyn C.; Vanak, Jill M.; Sweetenham, John; Moskowitz, Alison J.

In: British Journal of Haematology, Vol. 153, No. 3, 01.05.2011, p. 358-363.

Research output: Contribution to journalArticle

Smith, SD, Moskowitz, C, Dean, R, Pohlman, B, Sobecks, R, Copelan, E, Andresen, S, Bolwell, B, Maragulia, JC, Vanak, JM, Sweetenham, J & Moskowitz, AJ 2011, 'Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: Results from two transplant centres', British Journal of Haematology, vol. 153, no. 3, pp. 358-363. https://doi.org/10.1111/j.1365-2141.2011.08616.x
Smith, Stephen D. ; Moskowitz, Craig ; Dean, Robert ; Pohlman, Brad ; Sobecks, Ronald ; Copelan, Edward ; Andresen, Steven ; Bolwell, Brian ; Maragulia, Jocelyn C. ; Vanak, Jill M. ; Sweetenham, John ; Moskowitz, Alison J. / Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma : Results from two transplant centres. In: British Journal of Haematology. 2011 ; Vol. 153, No. 3. pp. 358-363.
@article{889d74a5146e492aa9f871d2ac495fb5,
title = "Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: Results from two transplant centres",
abstract = "Prior series have demonstrated that early relapsed (within 1year) or refractory Hodgkin lymphoma (HL) is associated with poor prognosis. To determine the outcome for patients with early relapsed/refractory HL in the modern era, we combined data from two large transplant centres, Cleveland Clinic Taussig Cancer Institute (CCTCI) and Memorial Sloan-Kettering Cancer Center (MSKCC), and analysed consecutive patients transplanted for relapsed/refractory HL following induction failure or remission durations of <1year. Two hundred and fourteen patients were analysed and the event-free survival (EFS) and overall survival (OS) at 6years for all patients were 45{\%} and 55{\%}, respectively. Factors significant for prognosis in multivariate analysis were extranodal disease and bulky disease (≥5cm). Patients with 0, 1, or 2 risk factors achieved 6year EFS of 65{\%}, 47{\%}, and 24{\%} and 6year OS of 81{\%}, 55{\%}, and 27{\%}, respectively. Patients with the sole risk factor of early relapsed/refractory disease achieved good outcomes in this large series; however the presence of bulk and/or extranodal disease significantly reduced EFS and OS. Patients with these additional risk factors are best suited for clinical trials investigating novel salvage regimens and post-transplant maintenance strategies.",
keywords = "Hodgkin lymphoma, Refractory, Relapse, Stem cell transplantation",
author = "Smith, {Stephen D.} and Craig Moskowitz and Robert Dean and Brad Pohlman and Ronald Sobecks and Edward Copelan and Steven Andresen and Brian Bolwell and Maragulia, {Jocelyn C.} and Vanak, {Jill M.} and John Sweetenham and Moskowitz, {Alison J.}",
year = "2011",
month = "5",
day = "1",
doi = "10.1111/j.1365-2141.2011.08616.x",
language = "English (US)",
volume = "153",
pages = "358--363",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma

T2 - Results from two transplant centres

AU - Smith, Stephen D.

AU - Moskowitz, Craig

AU - Dean, Robert

AU - Pohlman, Brad

AU - Sobecks, Ronald

AU - Copelan, Edward

AU - Andresen, Steven

AU - Bolwell, Brian

AU - Maragulia, Jocelyn C.

AU - Vanak, Jill M.

AU - Sweetenham, John

AU - Moskowitz, Alison J.

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Prior series have demonstrated that early relapsed (within 1year) or refractory Hodgkin lymphoma (HL) is associated with poor prognosis. To determine the outcome for patients with early relapsed/refractory HL in the modern era, we combined data from two large transplant centres, Cleveland Clinic Taussig Cancer Institute (CCTCI) and Memorial Sloan-Kettering Cancer Center (MSKCC), and analysed consecutive patients transplanted for relapsed/refractory HL following induction failure or remission durations of <1year. Two hundred and fourteen patients were analysed and the event-free survival (EFS) and overall survival (OS) at 6years for all patients were 45% and 55%, respectively. Factors significant for prognosis in multivariate analysis were extranodal disease and bulky disease (≥5cm). Patients with 0, 1, or 2 risk factors achieved 6year EFS of 65%, 47%, and 24% and 6year OS of 81%, 55%, and 27%, respectively. Patients with the sole risk factor of early relapsed/refractory disease achieved good outcomes in this large series; however the presence of bulk and/or extranodal disease significantly reduced EFS and OS. Patients with these additional risk factors are best suited for clinical trials investigating novel salvage regimens and post-transplant maintenance strategies.

AB - Prior series have demonstrated that early relapsed (within 1year) or refractory Hodgkin lymphoma (HL) is associated with poor prognosis. To determine the outcome for patients with early relapsed/refractory HL in the modern era, we combined data from two large transplant centres, Cleveland Clinic Taussig Cancer Institute (CCTCI) and Memorial Sloan-Kettering Cancer Center (MSKCC), and analysed consecutive patients transplanted for relapsed/refractory HL following induction failure or remission durations of <1year. Two hundred and fourteen patients were analysed and the event-free survival (EFS) and overall survival (OS) at 6years for all patients were 45% and 55%, respectively. Factors significant for prognosis in multivariate analysis were extranodal disease and bulky disease (≥5cm). Patients with 0, 1, or 2 risk factors achieved 6year EFS of 65%, 47%, and 24% and 6year OS of 81%, 55%, and 27%, respectively. Patients with the sole risk factor of early relapsed/refractory disease achieved good outcomes in this large series; however the presence of bulk and/or extranodal disease significantly reduced EFS and OS. Patients with these additional risk factors are best suited for clinical trials investigating novel salvage regimens and post-transplant maintenance strategies.

KW - Hodgkin lymphoma

KW - Refractory

KW - Relapse

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=79953907334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953907334&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2011.08616.x

DO - 10.1111/j.1365-2141.2011.08616.x

M3 - Article

C2 - 21410449

AN - SCOPUS:79953907334

VL - 153

SP - 358

EP - 363

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -